High-dose therapy for follicular lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Advanced-stage follicular non-Hodgkin's lymphoma (NHL) often shows resistance to conventional therapies.
• Relapsed follicular NHL necessitates exploring advanced treatment modalities like high-dose therapy with stem-cell transplantation.

Purpose of the Study:

• To evaluate the efficacy of high-dose therapy and stem-cell transplantation in follicular NHL.
• To analyze outcomes based on disease status (relapse vs. first remission) and transformation.
• To investigate the impact of minimal residual disease and potential immunomodulatory strategies.

Main Methods:

• Review of studies on autologous and allogeneic stem-cell transplantation for follicular NHL.
• Analysis of disease-free survival rates in relation to transplantation timing and disease status.
• Exploration of prognostic factors such as minimal residual disease and histologic transformation.

Main Results:

• Autologous transplantation in sensitive relapse yields approximately 40% disease-free survival.
• Allogeneic transplantation shows a 15% relapse rate, 50% overall survival, and 40% treatment-related mortality.
• Minimal residual disease presence predicts recurrence, highlighting its importance in treatment stratification.

Conclusions:

• High-dose therapy with autologous stem-cell transplantation is a viable option for relapsed follicular NHL, though controversial in first remission.
• Allogeneic transplantation has significant associated risks, necessitating careful patient selection.
• Targeting minimal residual disease and employing immunomodulatory strategies hold promise for enhancing outcomes in high-risk patients.